Cotinga Pharmaceuticals Kapitalrendite
Was ist das Kapitalrendite von Cotinga Pharmaceuticals?
Kapitalrendite von Cotinga Pharmaceuticals, Inc. ist 91.05%
Was ist die Definition von Kapitalrendite?
Die Eigenkapitalrendite ist ein Maß für die Rentabilität eines Unternehmens im Verhältnis zum Buchwert des Eigenkapitals. Sie wird berechnet, indem das Nettoergebnis des Geschäftsjahres durch das gesamte Eigenkapital geteilt wird.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Kapitalrendite von Unternehmen in Health Care Sektor auf TSXV im Vergleich zu Cotinga Pharmaceuticals
Was macht Cotinga Pharmaceuticals?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Unternehmen mit kapitalrendite ähnlich Cotinga Pharmaceuticals
- Eramet SA hat Kapitalrendite von 90.29%
- Eramet SA hat Kapitalrendite von 90.29%
- MX Gold hat Kapitalrendite von 90.37%
- Sysco hat Kapitalrendite von 90.53%
- Persta Resources hat Kapitalrendite von 90.73%
- Dynavax Technologies hat Kapitalrendite von 90.76%
- Cotinga Pharmaceuticals hat Kapitalrendite von 91.05%
- GNC hat Kapitalrendite von 91.72%
- InZinc Mining hat Kapitalrendite von 91.77%
- StrikeForce Technologies hat Kapitalrendite von 91.78%
- Sysco hat Kapitalrendite von 92.10%
- AgeX Therapeutics Inc hat Kapitalrendite von 92.32%
- SPORTTOTAL AG hat Kapitalrendite von 92.35%